OTC Statin Physician Follow-Up Label Comprehension Not Shown - FDA
This article was originally published in The Tan Sheet
Executive Summary
Merck and Bristol Myers-Squibb should design label comprehension studies that do not assume consumers would understand how to use Mevacor and Pravachol in an OTC setting, FDA's Karen Lechter, PhD, advised during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13-14.
You may also be interested in...
Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins
A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show
Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins
A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show
Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins
A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show